DDrare: Database of Drug Development for Rare Diseases

26. HTLV-1関連脊髄症
［臨床試験数：26，薬物数：46（DrugBank：27），標的遺伝子数：37，標的パスウェイ数：123］

Searched query = "HTLV-1-associated myelopathy", "Tropical spastic paraparesis", "HTLV-1", "HTLV-I-associated myelopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Amniotic Epithelial Cells; Amniotic epithelial cells; Bortezomib; Ciclosporin; Costicosteroids; Cyclophosphamide; Doxorubicin; Doxorubicin Hydrochloride; Doxorubicin hydrochloride; Etoposide; Filgrastim; Hu MiK-Beta-1; Human interferon beta; Interferon alfa; Interferon beta; Interferon beta-1a; KW-0761; KW-0761 0.3 mg/kg IV; Lamivudine; Lenalidomide; Methylprednisolone; Mogamulizumab; NK Cells; NK cells; Nivolumab; Other: Laboratory Biomarker Analysis; Other: Pharmacogenomic Study; Pentosan polysulfate; Pentoxifylline; Prednisolone; Prednisone; Propantheline; Propantheline Bromide; Raltegravir; Raltegravir and Zidovudine; Recombinant human interferon beta-1a; Recombinant interferon alfa; Sulfate; Tamibarotene; Valproic acid; Valproid acid plus corticosteroids; Vincristine; Vincristine Sulfate; Vincristine sulfate; Zidovudine; Zidovudine/lamivudine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02655471 (ClinicalTrials.gov)	July 1, 2017	16/11/2015	Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection	Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study	HTLV-I Infections;Tropical Spastic Paraparesis	Drug: Raltegravir and Zidovudine	Universidad Peruana Cayetano Heredia	Merck Sharp & Dohme Corp.	Completed	18 Years	N/A	All	10	Early Phase 1	Peru
2	NCT01867320 (ClinicalTrials.gov)	September 5, 2013	21/5/2013	Raltegravir for HAM/TSP	Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP)	HTLV-I Infection	Drug: Raltegravir	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	18 Years	N/A	All	19	Early Phase 1	United States
3	NCT01620736 (ClinicalTrials.gov)	January 2012	25/1/2012	Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load	Phase II Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load	Human T-cell Leukemia Virus Type 1 Infection	Drug: Raltegravir	Washington University School of Medicine	Merck Sharp & Dohme Corp.	Withdrawn	18 Years	N/A	All	0	Phase 2	United States
4	NCT01000285 (ClinicalTrials.gov)	September 2010	19/10/2009	EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma	Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma	Leukemia-Lymphoma, Adult T-Cell	Drug: Bortezomib;Drug: Etoposide;Drug: Vincristine;Drug: Doxorubicin;Drug: Prednisone;Drug: Cyclophosphamide;Drug: Raltegravir	Washington University School of Medicine	NULL	Completed	18 Years	N/A	All	18	Phase 1;Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02655471
(ClinicalTrials.gov)

July 1, 2017

16/11/2015

Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection

Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study

HTLV-I Infections;Tropical Spastic Paraparesis

Drug: Raltegravir and Zidovudine

Universidad Peruana Cayetano Heredia

Merck Sharp & Dohme Corp.

Completed

18 Years

N/A

All

Early Phase 1

Peru

NCT01867320
(ClinicalTrials.gov)

September 5, 2013

21/5/2013

Raltegravir for HAM/TSP

Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP)

HTLV-I Infection

Drug: Raltegravir

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

18 Years

N/A

All

Early Phase 1

United States

NCT01620736
(ClinicalTrials.gov)

January 2012

25/1/2012

Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load

Phase II Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load

Human T-cell Leukemia Virus Type 1 Infection

Drug: Raltegravir

Washington University School of Medicine

Merck Sharp & Dohme Corp.

Withdrawn

18 Years

N/A

All

Phase 2

United States

NCT01000285
(ClinicalTrials.gov)

September 2010

19/10/2009

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma

Leukemia-Lymphoma, Adult T-Cell

Drug: Bortezomib;Drug: Etoposide;Drug: Vincristine;Drug: Doxorubicin;Drug: Prednisone;Drug: Cyclophosphamide;Drug: Raltegravir

Washington University School of Medicine

NULL

Completed

18 Years

N/A

All

Phase 1;Phase 2

United States